[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336776-105":59,"doc-detail-336776-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","overcoming-antigen-escape-and-t-cell-exhaustion-in-car-t-therapy-for-leukemia","Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia","","Leukemia is a prevalent pediatric cancer with major challenges in relapsed or refractory settings. Chimeric antigen receptor T-cell (CAR-T) therapy is reviewed as a personalized approach that reprograms T cells to recognize and destroy resistant malignant cells. The review focuses on key limitations, especially antigen escape and T-cell exhaustion, and discusses dual-targeting strategies to preserve antigen recognition. It also analyzes exhaustion biology and methods to improve CAR-T persistence and efficacy, while noting risks including CRS and ICANS.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/overcoming-antigen-escape-and-t-cell-exhaustion-in-car-t-therapy-for-leukemia/336776/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/overcoming-antigen-escape-and-t-cell-exhaustion-in-car-t-therapy-for-leukemia/336776.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What are the main obstacles to effective CAR-T therapy in leukemia discussed in the review?","Question",{"text":112,"@type":113},"The review highlights antigen escape and T-cell exhaustion as primary barriers. It also considers how these mechanisms reduce sustained recognition and function of CAR-T cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do dual-targeting strategies help improve CAR-T outcomes?",{"text":117,"@type":113},"Dual-targeting aims to reduce the loss of target antigens. By engaging more than one target, it can help prevent treatment failure driven by antigen escape.",{"name":119,"@type":110,"acceptedAnswer":120},"What treatment-related risks are emphasized alongside CAR-T successes?",{"text":121,"@type":113},"Despite clinical successes, the review notes risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).",{"name":123,"@type":110,"acceptedAnswer":124},"Why is ongoing research considered necessary for CAR-T therapy in leukemia?",{"text":125,"@type":113},"The review concludes that further research is needed to optimize CAR-T use, reduce toxicities, and broaden applicability across hematologic malignancies.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},336776,1790193178,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":19,"preview_urls":149},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","cells  \nReview  \nOvercoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia  \nElbieta Bartoszewska 1,2, *,†, Maciej Tota 1,2,†, Monika Kisielewska 1,2, Izabela Skowron 1,2,  \nKamil Sebastianka 1,2, Oliwia Stefaniak 1,2, Klaudia Molik 1,2, Jakub Rubin 1,2, Karolina Kraska 1,2 and Anna Choroma ´nska 3, *  \nCitation: Bartoszewska, E.; Tota, M.; Kisielewska, M.; Skowron, I.; Sebastianka, K.; Stefaniak, O.; Molik, K.; Rubin, J.; Kraska, K.;  \nChoroma ´nska, A. Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia. Cells 2024, 13, 1596. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cells13181596](10.3390/cells13181596)  \nAcademic Editor: João T. Barata  \nReceived: 20 August 2024  \nRevised: 18 September 2024  \nAccepted: 20 September 2024  \nPublished: 23 September 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Faculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 5, 50-345 Wroclaw, Poland; [monika.kisielewska@student.umw.edu.pl](monika.kisielewska@student.umw.edu.pl) (M.K.); [izabela.skowron@student.umw.edu.pl](izabela.skowron@student.umw.edu.pl) (I.S.); [kamil.sebastianka@student.umw.edu.pl](kamil.sebastianka@student.umw.edu.pl) (K.S.); [oliwia.stefaniak@student.umw.edu.pl](oliwia.stefaniak@student.umw.edu.pl) (O.S.); [klaudia.molik@student.umw.edu.pl](klaudia.molik@student.umw.edu.pl) (K.M.); [jakub.rubin@student.umw.edu.pl](jakub.rubin@student.umw.edu.pl) (J.R.); [karolina.kraska@student.umw.edu.pl](karolina.kraska@student.umw.edu.pl) (K.K.)  \n2 Student Research Group No K148, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland  \n3 Department of Molecular and Cellular Biology, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland  \n* Correspondence: [elzbieta.bartoszewska@student.umw.edu.pl](elzbieta.bartoszewska@student.umw.edu.pl) (E.B.); [anna.choromanska@umw.edu.pl](anna.choromanska@umw.edu.pl) (A.C.)† These authors contributed equally to this work.  \nAbstract: Leukemia is a prevalent pediatric cancer with significant challenges, particularly in relapsedor refractory cases. Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a personalized cancer treatment, modifying patients’ T cells to target and destroy resistant cancer cells. This study reviews the current therapeutic options of CAR-T therapy for leukemia, addressing the primary obstacles such as antigen escape and T-cell exhaustion. We explore dual-targeting strategies and their potential to improve treatment outcomes by preventing the loss of target antigens. Additionally, we examine the mechanisms of T-cell exhaustion and strategies to enhance CAR-T persistence and effectiveness. Despite remarkable clinical successes, CAR-T therapy poses risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) . Our findings highlight the need for ongoing research to optimize CAR-T applications, reduce toxicities, and extend this innovative therapy to a broader range of hematologic malignancies. This comprehensive review aims to provide valuable insights for improving leukemia treatment and advancing the field of cancer immunotherapy.  \nKeywords: leukemia; pediatric oncology; CAR-T therapy; acute lymphoblastic leukemia; acute myeloid leukemia; antigen escape; T-cell exhaustion; cytokine release syndrome; immune effector cell-associated neurotoxicity syndrome; dual-targeting CAR-Ts  \n1. Introduction  \n1.1. Leukemia  \nLeukemia is the most frequently diagnosed oncologic condition among the pediatric patient population [1] . In 2022, leukemia was the 13th most commonly diagnosed malign","cbCaiqNubhmiOdKC","https://ap.wps.com/l/cbCaiqNubhmiOdKC","pdf",990661,"English","# Abstract\n# Keywords\n# 1. Introduction\n## 1.1. Leukemia","[{\"question\":\"What are the main obstacles to effective CAR-T therapy in leukemia discussed in the review?\",\"answer\":\"The review highlights antigen escape and T-cell exhaustion as primary barriers. It also considers how these mechanisms reduce sustained recognition and function of CAR-T cells.\"},{\"question\":\"How do dual-targeting strategies help improve CAR-T outcomes?\",\"answer\":\"Dual-targeting aims to reduce the loss of target antigens. By engaging more than one target, it can help prevent treatment failure driven by antigen escape.\"},{\"question\":\"What treatment-related risks are emphasized alongside CAR-T successes?\",\"answer\":\"Despite clinical successes, the review notes risks such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).\"},{\"question\":\"Why is ongoing research considered necessary for CAR-T therapy in leukemia?\",\"answer\":\"The review concludes that further research is needed to optimize CAR-T use, reduce toxicities, and broaden applicability across hematologic malignancies.\"}]","Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia | PDF",1790016571,48,[150,154,158,162],{"page_no":8,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cece72c252dc301b460100bd10a1f02.webp",983,1390,{"page_no":14,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c26483ca8a82ccefe2544f882e91b1b.webp",982,1388,{"page_no":81,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/181be273213346a2ff2df662ad5e9796.webp",981,1387,{"page_no":19,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de29a737593ea7db423783a2da451221.webp",980,1385]